3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
34
Dermatologic
4
Sarcoma
3
Gynecologic
3
Tumor-Agnostic
2
Other solid neoplasm
2
Gastrointestinal
2
Thoracic
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Endocrine
1
CNS
1
Conditions
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
551
Pemetrexed
404
Cisplatin
401
Paclitaxel
273
Docetaxel
255
Gemcitabine
218
pembrolizumab
191
Bevacizumab
190
Erlotinib Hydrochloride
184
Radiotherapy
181
Etoposide
147
durvalumab
140
Nivolumab
134
Drug Therapy
127
osimertinib
107
atezolizumab
92
Gefitinib
74
Radiosurgery
72
anlotinib
69
Vinorelbine
68
tislelizumab
52
Irinotecan
51
Ipilimumab
50
130-nm albumin-bound paclitaxel
50
Taxes
48
Surgical Procedures, Operative
46
Cetuximab
46
sintilimab
45
Albumin-Bound Paclitaxel
45
apatinib
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
ribociclib
×
Thoracic
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts